The Hidden Cost of Choosing the Wrong CRO

The protocol was elegant. The science was sound. On paper, the Phase 1/2 program looked like it would move cleanly from first patient in to meaningful signal.

But somewhere between kickoff and execution, things began to drift—missed milestones explained away in status calls, familiar faces replaced by new ones, metrics that looked reassuring but said very little. No single moment of failure. Just a slow unraveling.

By the time the sponsor fully understood what was happening, 12 months had slipped by. Costs had ballooned. Internal teams were spending more time managing the CRO than advancing the program. And investors—once energized—began asking harder questions, with less patience.

The uncomfortable truth? This outcome is rarely about the science.

More often, it’s the result of how the CRO was selected—and how the relationship was governed.

What if CRO selection and governance were treated as a core part of your development strategy instead of a rushed procurement exercise?

The difference is not subtle. Effective sponsors approach this with intention: alignment on operating model before contracts are signed, absolute clarity on accountability, governance structures that are fit for purpose—not overly bureaucratic, but not passive either—and a proactive approach to risk that surfaces issues early, when they are still solvable.

In other words, they treat the CRO not as a vendor, but as a strategic extension of themselves.

Experienced operators recognize this pattern early because they have lived it. They know that the work isn’t only in selecting a CRO; it’s also in designing the conditions under which that CRO can succeed.

Most sponsors reading this are already somewhere in the middle of it. The FAQ on CRO fit and course correction covers what tends to help.